doi: 10.1016/0920-9964(88)90025-4.
Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia
Affiliations
- PMID: 3154530
- DOI: 10.1016/0920-9964(88)90025-4
Item in Clipboard
Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia
Schizophr Res.
1988 Nov-Dec.
Abstract
A sensitive radioimmunoassay was developed to determine the steady-state, fixed-dose pharmacokinetic profile of fluphenazine decanoate in nine outpatients. To see if neuroleptic blood levels measured by this assay correlated with a clinical event, we performed a cross-sectional study of fluphenazine blood levels in 11 patients with and 17 patients without tardive dyskinesia. The results do not support the hypothesis that fluphenazine decanoate serum levels correlate with TD occurrence.
Similar articles
-
Fluphenazine decanoate and tardive dyskinesia: a possible association.Am J Psychiatry. 1981 Oct;138(10):1362-5. doi: 10.1176/ajp.138.10.1362. Am J Psychiatry. 1981. PMID: 7294195
-
Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.Br J Psychiatry. 1991 May;158:658-65. doi: 10.1192/bjp.158.5.658. Br J Psychiatry. 1991. PMID: 1860020 Clinical Trial.
-
Fluphenazine decanoate and tardive dyskinesia.Am J Psychiatry. 1982 Jul;139(7):969-70. Am J Psychiatry. 1982. PMID: 6124136 No abstract available.
-
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.J Psychiatry Neurosci. 1994 Jul;19(4):254-64. J Psychiatry Neurosci. 1994. PMID: 7918346 Free PMC article. Review.
-
The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia.Mov Disord. 1993 Oct;8(4):445-52. doi: 10.1002/mds.870080405. Mov Disord. 1993. PMID: 7901759 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
